Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Reinforcing the social compromise of accelerated approval

Accelerated approval enables investigational drugs to reach the US market on the basis of their demonstrated effects in unvalidated surrogate measures, only reasonably likely to predict clinical response. To fulfil the social compromise, regulators should ensure that confirmatory trials testing clinically meaningful end points are already underway at the time of approval.

This is a preview of subscription content

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Beaver, J. A. et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 4, 849–856 (2018).

    Article  Google Scholar 

  2. 2.

    Kesselheim, A. S. et al. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. BMJ 351, h4633 (2015).

    Article  Google Scholar 

  3. 3.

    Naci, H., Smalley, K. R. & Kesselheim, A. S. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration. JAMA 318, 626–636 (2017).

    Article  Google Scholar 

  4. 4.

    Zettler, M. & Nabhan, C. Fulfillment of postmarketing requirements to the FDA for therapies granted oncology indications between 2011 and 2016. JAMA Oncol. (2018).

    Article  PubMed  Google Scholar 

  5. 5.

    FDA. Postmarket requirements and commitments database. FDA (2018).

  6. 6.

    Meadows, M. Promoting safe and effective drugs for 100 years. FDA (2006).

  7. 7.

    Gellad, W. F. & Kesselheim, A. S. Accelerated approval and expensive drugs — a challenging combination. N. Engl. J. Med. 376, 2001–2004 (2017).

    Article  Google Scholar 

  8. 8.

    Vivot, A. et al. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann. Oncol. 28, 1111–1116 (2017).

    CAS  Article  Google Scholar 

Download references


The work of A.S.K. and B.G. on this project was funded by the Laura and John Arnold Foundation. A.S.K. receives grant support from the Engelberg Foundation and the Harvard Program in Therapeutic Science. These funders had no role in any aspect related to the publication of this manuscript.

Author information



Corresponding author

Correspondence to Aaron S. Kesselheim.

Ethics declarations

Competing interests

A.S.K. has received unrelated research funding from the FDA Division of Health Communication and Office of Generic Drugs (2013–2016). B.G. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gyawali, B., Kesselheim, A.S. Reinforcing the social compromise of accelerated approval. Nat Rev Clin Oncol 15, 596–597 (2018).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing